Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer

Mark T. Fleming, Guru Sonpavde, Michael Kolodziej, Sanjay Awasthi, Thomas E. Hutson, Danko Martincic, Ashutosh Rastogi, Steven R. Rousey, Ralph E. Weinstein, Matthew D. Galsky, William R. Berry, Yunfei Wang, Kristi A. Boehm, Lina Asmar, Mary A. Rauch, Tomasz M. Beer

    Research output: Contribution to journalArticle

    27 Scopus citations

    Abstract

    Purpose: Cetuximab (C), a chimeric monoclonal antibody that binds epidermal growth factor receptor (EGFR), is active against androgen-independent prostate cancer cell lines and might enhance the activity of chemotherapy. The efficacy of combining cetuximab with mitoxantrone (M) plus prednisone (MP) was evaluated in progressive metastatic castrate-resistant prostate cancer (CRPC) after receiving docetaxel. Materials and Methods: Patients with progression after receiving docetaxel were eligible and randomized 2:1 to CMP or MP. Therapy was mitoxantrone 12 mg/m 2 intravenously (I.V.) on day 1, oral prednisone 10 mg daily in both arms, and cetuximab 250 mg/m 2 I.V. (400 mg/m 2 day 1, cycle 1) on days 1, 8, and 15 in the CMP arm. Cycles were repeated every 21 days. Radiologic assessments of disease and PSA (prostate-specific antigen) occurred every 4 cycles. The primary endpoint was time to progression (TTP). Results: A total of 115 patients were enrolled, 75 in the CMP and 40 in the MP arm: the median TTP was 4.9 and 6.6 months, respectively; the measurable disease response rate was 2% and 4%, the PSA response rate 7.7% and 17.6%, and median survival 11.9 and 15.7 months, respectively. Key grade 3-4 toxicities were neutropenia 44% and 25.6%, anemia 6.7% and 7.7%, thrombocytopenia 6.7% and 2.6%, and fatigue 8% in both arms. In an unplanned exploratory analysis, median TTP with (n = 24) and without rash (n = 51) in the CMP arm was 10.3 months vs. 2.8 months (P =.004). On multivariable analysis,rash was significantly associated with TTP (hazard ratio [HR] = 0.43; P =.01). Conclusions: The treatment with CMP is not recommended in unselected men with docetaxel-treated CRPC, although rash might help develop tailored therapy.

    Original languageEnglish (US)
    Pages (from-to)6-14
    Number of pages9
    JournalClinical Genitourinary Cancer
    Volume10
    Issue number1
    DOIs
    StatePublished - Mar 1 2012

    Keywords

    • Chemotherapy
    • Epidermal growth factor receptor inhibitors
    • Monoclonal antibody
    • Taxane

    ASJC Scopus subject areas

    • Oncology
    • Urology

    Fingerprint Dive into the research topics of 'Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Fleming, M. T., Sonpavde, G., Kolodziej, M., Awasthi, S., Hutson, T. E., Martincic, D., Rastogi, A., Rousey, S. R., Weinstein, R. E., Galsky, M. D., Berry, W. R., Wang, Y., Boehm, K. A., Asmar, L., Rauch, M. A., & Beer, T. M. (2012). Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. Clinical Genitourinary Cancer, 10(1), 6-14. https://doi.org/10.1016/j.clgc.2011.11.003